Oxytrol For Women Exclusivity Ends Not With Competition, But Label Warning Change
This article was originally published in The Tan Sheet
Executive Summary
Private labeler Perrigo has eyed launching a generic since FDA approved the 3.9mg oxybutynin transdermal as a first-in-class OTC in 2013. Currently, though, Perrigo says it is "not a big product" and is talking about other prescription OAB products that could be approved for OTC.
You may also be interested in...
Little Innovation In US OTC Switches For 20 Years, ACNU Won't Remove Impediments – Study
Of 45 switches since 2002, three added an indication to OTC market and three were “an exceptional innovation” offering “a genuinely novel OTC product, providing a new to OTC active pharmaceutical ingredient, pharmacological class, and indication,” Haleon researchers found.
UK Looks To Switch Overactive Bladder Treatment
Maxwellia is seeking its second first-in-class switch in the UK with an application to reclassify from prescription-only to pharmacy status overactive bladder treatment Aquiette.
Lady Patch For Preventing Bladder Leaks Wins P&G Ventures Innovation Challenge
ParaPatch developed patch to commercialize a home remedy and was chosen from a record number of submissions in contest. It will receive $10,000 and opportunity to partner with P&G Ventures to continue development.